Last update Dec. 25, 2022
Very Low Risk
Es un antibacteriano aminoglucósido semisintético derivado de la kanamicina. Se usa de manera similar a la gentamicina en el tratamiento de infecciones graves por bacterias gramnegativas y otras grampositivas. Administración intramuscular o intravenosa cada 8 a 12 horas.
Se excreta en leche materna en cantidad no detectable o clínicamente no significativa, muy inferior a la dosis utilizada en recién nacidos y lactantes. (Matsuda 1984 y 1974, Yuasa 1974)
Like other aminoglycosides, its very low oral bioavailability minimizes the passage into plasma of the infant from ingested breast milk, except in the premature and in the immediate neonatal period in which there may be greater intestinal permeability.
Authorized use in newborns and infants
Although rare, the possibility of transient gastroenteritis due to alteration of the intestinal flora in infants whose mothers take antibiotics should be taken into account. (Arbex 2010)
Several medical societies and expert authors consider the use of this medication to be safe during breastfeeding. (Hale, LactMed, Briggs 2015, Schaefer 2015, Baquero 2015, Chin 2001)
We do not have alternatives for Amikacin since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM